Cytokine and Stress Hormone Responses to Exercise-induced Hypoxemia Among Endurance-trained
Launched by GEPNER YFTACH · Mar 11, 2020
Trial Information
Current as of July 09, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Fifty highly trained endurance runners (men and women, age: 18-35 years) will be recruited for this study. The first testing session will serve as a screening tool to determine subject eligibility. Following the first testing sessions subjects will be divided into EIAH or non-EIAH groups based on SaO2 at VO2max (EIAH \< 93%, non-EIAH \> 95%; Dempsey and Wagner criteria). Subjects with intermediate SaO2 (93-95% at VO2max) values will be included in the study for correlational analyses only.
All subjects will be advised orally, and in writing, as to the nature of the experiments and will giv...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1) Physically active (minimum of 50 km running/week) and maximal oxygen consumption \> 55 and 50 ml/kg-1/min-1 for men and women, respectively.
- • 2) classified as low risk based on a medical questionnaire, body mass index and non-smoking status.
- • 3) No history of pulmonary, metabolic and/or cardiovascular disease.
- • 4) normal pulmonary function as defined by a ≥ 80% of predicted forced vital capacity (FVC), forced expired volume in one second (FEV1) and FEV1/FVC according the American Thoracic Society standards.
- Exclusion Criteria:
- • Smoking and/or any pulmonary, metabolic and/or cardiovascular disease.
- • maximal oxygen consumption lower than set criteria.
About Gepner Yftach
Gepner Yftach is a dedicated clinical trial sponsor specializing in the development and management of innovative therapies across various therapeutic areas. With a strong commitment to advancing medical science, Gepner Yftach focuses on conducting rigorous clinical research that adheres to the highest ethical standards and regulatory requirements. The organization collaborates with a network of healthcare professionals and research institutions to ensure the successful execution of clinical trials, aimed at providing safe and effective treatment options for patients. Their expertise in trial design, patient recruitment, and data analysis positions them as a key player in the pharmaceutical and biotechnology sectors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tel Aviv, , Israel
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials